Swedish digital healthcare provider Blodtrycksdoktorn has raised SEK 7 million from existing investors as it pivots its business model following a turbulent period marked by regional contract disputes.
From Rapid Growth to Sudden Setback
Based in Lund, Blodtrycksdoktorn focuses on digital care for hypertension management and weight loss—two of the most pressing and widespread health challenges globally.
The company experienced rapid growth throughout 2025 and was reportedly close to profitability. However, momentum was disrupted when Region Sörmland terminated its collaboration with the company and declined to pay outstanding invoices.
This unexpected move forced Blodtrycksdoktorn to reassess its operating model.
Strategic Pivot Underway
In response, the company is now shifting its business strategy—moving away from reliance on regional healthcare contracts toward a more sustainable and diversified model.
While details of the new approach remain limited, the transition reflects a broader trend in digital health: reducing dependency on public healthcare systems and exploring direct-to-consumer or hybrid care models.
Strong Investor Backing Despite Turbulence
Despite recent challenges, existing investors have doubled down on their support, injecting fresh capital into the company.
This SEK 7 million round signals continued belief in Blodtrycksdoktorn’s core offering and long-term potential, particularly as demand for remote and preventative healthcare solutions continues to rise.
Public Criticism and Industry Tensions
The situation has not been without controversy. CEO Jonas Wohlin has publicly criticized the doctors involved in reviewing the company, claiming conflicts of interest influenced the outcome.
The dispute highlights ongoing tensions between emerging digital healthcare providers and traditional healthcare systems—especially in regulated markets like Sweden.
Why This Matters
Hypertension and obesity are major global health concerns, and digital-first solutions like Blodtrycksdoktorn aim to make treatment more accessible and scalable.
However, the company’s situation underscores a key challenge in HealthTech: navigating public healthcare systems, regulatory frameworks, and institutional resistance while trying to innovate.
What’s Next
With new funding secured and a strategic pivot in motion, Blodtrycksdoktorn is entering a critical phase.
Its ability to adapt—both operationally and commercially—will determine whether it can regain growth momentum and solidify its position in the evolving digital healthcare landscape.
